NEMUS Bioscience: A Unique Approach To The 32 Million Rx U.S. Glaucoma Market
Dallas Salazar - at Seeking Alpha - Fri May 15, 11:42AM CDT
NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences
Marketwired - Fri May 15, 7:00AM CDT
NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids for the treatment of glaucoma, announces that it has been invited to, and will attend, three investor conferences where they will present and conduct one-on-one meetings with investors in May and June.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part VII
Anthony Cataldo - at Seeking Alpha - Sun Apr 19, 11:06PM CDT
NEMUS Bioscience, Inc. to Present on Cannabis Investor Webcast
ACCESSWIRE - Wed Apr 08, 6:16PM CDT
COSTA MESA, CA / ACCESSWIRE / April 8, 2015 / NEMUS Bioscience Inc. (NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, will be presenting on the Cannabis Investor Webcast on Thursday, April 9, 2015 at 5:00 PM ET.
NEMUS Bioscience, Inc. Retains MZ Group as Investor Relations Advisor
GlobeNewswire - Tue Mar 24, 6:09AM CDT
NEMUS Bioscience Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, announced today it has retained MZ Group as its investor relations advisor.
NEMUS Bioscience, Inc. initiates anti-infective program with focus on MRSA
GlobeNewswire - Wed Mar 18, 6:06AM CDT
NEMUS Bioscience, Inc. (OTCQB: NMUS) announced today that the company would begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics. The initial studies will be performed at the University of Mississippi (UM), a NEMUS strategic collaborative partner and a global leader in the chemistry and science of cannabinoids and botanicals.
Cannabis - The Good, The Bad And The Ugly
Nick Cox - at Seeking Alpha - Mon Mar 09, 4:02AM CDT
INSY: 59.00 (+0.17), GWPH: 112.25 (-0.07)
48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 112.25 (-0.07)
Nemus Unlocks Cannabinoid Potential with Unique Compound
ACCESSWIRE - Tue Feb 17, 8:33AM CST
WHITEFISH, MT / ACCESSWIRE / February 17, 2015 / The market for legalized marijuana grew 74% from $1.5 billion in 2013 to $2.7 billion in 2014, according to ArcView Market Research, with medical marijuana accounting for over 80% of the market. These growth rates are being driven by favorable legislation across the country and growing public support for the legalization of both adult-use and medical marijuana, although there's still strong opposition by a lot of conservatives in the government.
GWPH: 112.25 (-0.07), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22)
StockNewsNow.com Publishes New SNNLive Video Interview with NEMUS Bioscience, Inc.
ACCESSWIRE - Wed Feb 11, 7:31AM CST
LOS ANGELES, CA / ACCESSWIRE / February 11, 2015 / StockNewsNow.com, the Official MicroCap News Source, today published an SNNLive Video Interview with John Hollister, CEO of NEMUS Bioscience, Inc. (OTCBB: NMUS), a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics through partnership with the University of Mississippi for the treatment of a variety of diseases or symptoms suffered by many around the globe. The video interview was recorded in San Francisco, CA at the Healthcare Media Day.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 112.25 (-0.07)
NEMUS Bioscience Announces Appointment of Thomas A. George, CFO of Deckers Brands, to Its Board of Directors
GlobeNewswire - Mon Jan 12, 7:00AM CST
NEMUS Bioscience, Inc. (OTCQB:NMUS) announced the appointment of Thomas (Tom) A. George, current Chief Financial Officer of Deckers Brands (NYSE
DECK: 72.27 (-0.15)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 112.25 (-0.07)
NEMUS to Move Forward With Cannabinoid-Based Therapy for Open-Angle Glaucoma
GlobeNewswire - Thu Dec 04, 12:05PM CST
NEMUS Bioscience, Inc. (OTC:NMUS) reports that data recently presented at the American Association of Pharmaceutical Scientists (AAPS) meeting in San Diego by Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics, University of Mississippi, showed that a pro-drug formulation of Δ-tetrahydrocannabinol (THC), in-licensed from the University of Mississippi, achieved company goals of significantly lowering intra-ocular pressure (IOP) in an open-angle rabbit glaucoma model.